OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

Date of occurrence of the event: Sept 19, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI Pharma received a notice from the FDA for orphan drug designation for OBI-3424 in treating Acute Lymphoblastic Leukemia (abbreviated as ALL). […]

This article is password protected.

To view the content, please enter your password in the field below